Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LifewardLFWD +2.13%52 3-Year EBITDA Growth Rate is 17.50% as of Mar. 2026, which is 53% below its 10-year median of 36.90. GuruFocus rates LFWD with a GF Score™ of 52/100 and a GF Value™ of $13.82 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Lifeward ranks better than 63.1% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 18.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 48.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Lifeward was 72.50% per year. The lowest was -8.10% per year. And the median was 36.90% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Lifeward 3-Year EBITDA Growth Rate Related Terms
LFWD vs CSDX, CTSO, NMTC: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Lifeward's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifeward 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lifeward's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Lifeward's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.50% mean?
Lifeward (LFWD) has a 3-Year EBITDA Growth Rate of 17.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lifeward and its competitors. This is 53% below median its historical median of 36.90. According to the industry distribution chart, Lifeward ranks #255 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 36.9%.
Is Lifeward's 3-Year EBITDA Growth Rate too high?
Lifeward's current 3-Year EBITDA Growth Rate of 17.50% is 53% below median its 10-year median of 36.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. Lifeward's value of 17.50% is 116% above this industry median. Based on the distribution chart, Lifeward ranks #255 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Lifeward has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lifeward's 3-Year EBITDA Growth Rate compare to CSDX and CTSO?
According to the Medical Devices & Instruments industry distribution chart, Lifeward ranks #255 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Lifeward in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. Lifeward's value of 17.50% is 116% above this benchmark. While the company's 10-year median is 36.90 vs. the industry median of 8.10, Lifeward has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifeward's current 3-Year EBITDA Growth Rate of 17.50% is 116% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Lifeward and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifeward's current 3-Year EBITDA Growth Rate is 17.50%, which is 53% below median its own 10-year median of 36.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifeward stock overvalued right now?
Based on GuruFocus' analysis, Lifeward (LFWD) is currently considered Possible Value Trap. The stock's GF Value™ is $13.82, compared to a current price of $7.10 — trading 48.6% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.50%, which is 53% below median its 10-year median of 36.90 and 116% above the Medical Devices & Instruments industry median of 8.10. Lifeward's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Lifeward (LFWD), the current 3-Year EBITDA Growth Rate is 17.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifeward (LFWD) Overvalued in 2026?
Based on GuruFocus' analysis, Lifeward stock appears to be undervalued.
The current stock price of $7.10 is trading 48.6% below its estimated GF Value™ of $13.82.
GuruFocus considers Lifeward to be Possible Value Trap.
Key valuation signals for LFWD:
3-Year EBITDA Growth Rate: 17.50% (53% below median its 10-year median of 36.90)
GF Value™: $13.82 vs. price of $7.10 (48.6% below fair value)
Industry Position: 116% above the Medical Devices & Instruments median (#255 of 691)
No single metric tells the full story. See the LFWD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions spanning the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings include the ReWalk Personal Exoskeleton, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. The company operates in the United States, which generates the majority of its revenue, as well as in Europe, Germany, Asia Pacific, and the rest of the world.
52GF Score
Get the complete analysis for LFWD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFWD has been successfully added to your 
